According to the 2017 and 2022 European Leukemia Net (ELN) risk stratifications, mutated ASXL1 defines an adverse‐risk subgroup of AML except for the coexistence with favorable‐risk AML subtypes [3, 4]. Here, ASXL1 is linked to acute myeloid leukemia.